Market Overview

According to fortune business insights, the global clinical trial supplies market size was valued at USD 5.45 billion in 2025. The market is projected to grow from USD 5.83 billion in 2026 to USD 11.80 billion by 2034, exhibiting a CAGR of 9.2% during the forecast period. North America dominated the clinical trial supplies market with a market share of 38.16% in 2025.

The analysis shows that top companies are investing more in innovative services as the number of clinical trials for biologics, medical devices, and other therapies increases. The growing R&D investment among pharmaceutical and biotech companies and the expansion of hybrid and decentralized trials are driving the adoption of end-to-end supply management solutions. This trend indicates strong demand for clinical trial supplies worldwide.

Major Players Profiled in the Market Report:

• Thermo Fisher Scientific Inc. (U.S.)
• Parexel International (MA) Corporation (U.S.)
• Catalent Inc. (U.S.)
• Almac Group (U.K.)
• PCI Pharma Services (U.S.)
• Clinigen Limited (U.K.)
• Myonex (U.S.)
• Biocair (U.K.)
• Oximio (U.K.)
• KLIFO (Denmark)

Segments

Rising Demand for DTP and Outsourcing to Propel Services Segment Growth

Based on type, the market is divided into products and services. The services segment holds the largest market share owing to the increasing trend of outsourcing supply chain management, including clinical supply planning, packaging, storage, cold-chain distribution, and Direct-To-Patient (DTP) delivery.

Large Scale and Complexity of Trials to Drive Phase III Segment Expansion

By phase, the market is categorized into phase I, phase II, phase III, and phase IV. The phase III segment is leading the market, driven by the large number of patients, longer duration, and global scale of Phase III trials, which require extensive and complex supply management.

Easier Manufacturing and Formulation to Dominate Small Molecules Segment